AMNEAL PHARMACEUTICALS, INC. $AMRX Shares Bought by Deutsche Bank AG

Key Points

• Deutsche Bank AG has increased its stake in Amneal Pharmaceuticals by 128.3%, owning 305,621 shares valued at approximately $2.56 million.
• Analysts have set an average price target of $11.60 for Amneal Pharmaceuticals, with five analysts rating the stock as a "Buy".
• Insider transactions show executives sold shares totaling $666,037 and $302,595 recently, reflecting a decrease in their ownership stakes.

Deutsche Bank AG lifted its holdings in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) by 128.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 305,621 shares of the company's stock after buying an additional 171,735 shares during the quarter. Deutsche Bank AG owned 0.10% of AMNEAL PHARMACEUTICALS worth $2,561,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Amalgamated Bank boosted its stake in shares of AMNEAL PHARMACEUTICALS by 33.0% in the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after buying an additional 1,367 shares in the last quarter. GF Fund Management CO. LTD. boosted its stake in shares of AMNEAL PHARMACEUTICALS by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 7,934 shares of the company's stock valued at $66,000 after buying an additional 1,428 shares in the last quarter. Xponance Inc. boosted its stake in shares of AMNEAL PHARMACEUTICALS by 16.1% in the first quarter. Xponance Inc. now owns 13,183 shares of the company's stock valued at $110,000 after buying an additional 1,828 shares in the last quarter. MetLife Investment Management LLC boosted its stake in shares of AMNEAL PHARMACEUTICALS by 2.5% in the fourth quarter. MetLife Investment Management LLC now owns 94,639 shares of the company's stock valued at $750,000 after buying an additional 2,297 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of AMNEAL PHARMACEUTICALS by 3.3% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 90,460 shares of the company's stock valued at $716,000 after buying an additional 2,911 shares in the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at AMNEAL PHARMACEUTICALS

In other news, EVP Jason B. Daly sold 22,000 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total value of $199,100.00. Following the completion of the transaction, the executive vice president directly owned 10,606 shares of the company's stock, valued at $95,984.30. The trade was a 67.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Andrew S. Boyer sold 279,244 shares of the business's stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total value of $2,619,308.72. Following the completion of the transaction, the executive vice president directly owned 152,426 shares of the company's stock, valued at approximately $1,429,755.88. This trade represents a 64.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 577,206 shares of company stock valued at $5,405,265 over the last three months. 17.45% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have commented on AMRX. Wall Street Zen downgraded AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. The Goldman Sachs Group began coverage on AMNEAL PHARMACEUTICALS in a research report on Friday, June 6th. They set a "buy" rating and a $12.00 target price on the stock. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, AMNEAL PHARMACEUTICALS has a consensus rating of "Buy" and a consensus price target of $11.60.

AMNEAL PHARMACEUTICALS Price Performance

AMRX traded down $0.31 during trading on Monday, reaching $9.28. 1,111,483 shares of the stock were exchanged, compared to its average volume of 1,726,976. The business's 50 day moving average price is $8.40 and its two-hundred day moving average price is $8.02. The company has a market capitalization of $2.91 billion, a price-to-earnings ratio of 928.93 and a beta of 1.11. AMNEAL PHARMACEUTICALS, INC. has a 1 year low of $6.68 and a 1 year high of $9.79.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. On average, analysts anticipate that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current year.

AMNEAL PHARMACEUTICALS Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.